Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-ras oligonucleotide hybridization in 78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal ovaries. A cut-off value of an integral of absorbance (i.a.) of 2.20, obtained by receiver operating characteristic (ROC) curve, was shown to be the best cut-off for defining p21 positivity. p21 levels were higher in malignant tumours than in benign tumours (median 2.10 i.a. vs median 1.22 i.a.; P = 0.014) and in omental metastases than in primary ovarian carcinomas (median 2.54 i.a. vs median 2.1 i.a.; P = 0.0089). p21 overexpression did not correlate with any of the clinicopathological parameters examined. Follow-up data were available for 63 patients. A significant relationship was shown between p21 positivity and a shorter overall survival (OS) (P < 0.03) and progression-free survival (PFS) (P < 0.03). In multivariate analysis only the presence of ascites, p21 levels and epidermal growth factor receptor status retained an independent prognostic role. K-ras gene mutations were frequently detected in benign and low malignant potential tumours (71.4%), which were mostly mucinous (P = 0.0152).
展开▼
机译：通过蛋白质印迹和/或K-ras寡核苷酸杂交分析了78例原发性卵巢癌，20例网膜转移，2例低度恶性潜在肿瘤（LMP），9例良性卵巢肿瘤和10例正常卵巢的Ras / p21癌蛋白表达和K-ras突变。通过接收器工作特性（ROC）曲线获得的吸光度（i.a.）积分的临界值为2.20，它是定义p21阳性的最佳临界值。在恶性肿瘤中，p21水平高于良性肿瘤（中位值为2.10，相对于中位值为1.22; P = 0.014）和网膜转移中的原发性卵巢癌（中位值为2.54，相对于中位值为2.1; P = 0.0089）。 p21过表达与所检查的任何临床病理参数均不相关。有63位患者的随访数据。在p21阳性与较短的总生存期（OS）（P <0.03）和无进展生存期（PFS）（P <0.03）之间显示出显着的关系。在多变量分析中，只有腹水，p21水平和表皮生长因子受体状态的存在才具有独立的预后作用。在良性和低恶性潜能肿瘤（71.4％）中经常检测到K-ras基因突变，其中大多数为粘液性（P = 0.0152）。
展开▼
